<p>Prestige Consumer Healthcare Inc.（紐約證券交易所代碼：PBH - 免費報告）- Zacks Research 在 12 月 23 日（星期二）發佈的報告中上調了 Prestige Consumer Healthcare 2027 年第一季度每股收益的預期。Zacks Research 分析師團隊現在預測該公司本季度每股收益為 1.24 美元，高於之前預測的 1.23 美元。Zacks Research 目前對該股票的評級為 “持有”。Prestige Consumer Healthcare 當前全年的每股收益共識預期為 4.50 美元。</p>
<p>Prestige Consumer Healthcare（紐約證券交易所代碼：PBH - 獲取免費報告）最近於 11 月 6 日（星期四）公佈了季度財報。該公司報告本季度每股收益為 1.07 美元，超出市場共識預期的 0.97 美元，超出幅度為 0.10 美元。該業務本季度的收入為 2.7411 億美元，而分析師預期為 2.5714 億美元。Prestige Consumer Healthcare 的淨利潤率為 18.09%，股本回報率為 12.43%。與去年同期相比，該公司的季度收入下降了 3.4%。去年同期，該公司每股收益為 1.09 美元。Prestige Consumer Healthcare 已將 2026 財年的指導目標設定為每股收益 4.540-4.580 美元。</p>
<p>其他幾位股票分析師最近也對 PBH 發表了看法。Jefferies Financial Group 在 10 月 27 日（星期一）的研究報告中將 Prestige Consumer Healthcare 的目標價從 75.00 美元下調至 71.00 美元，並對該股票給予 “持有” 評級。Canaccord Genuity Group 在 11 月 7 日（星期五）的研究報告中將 Prestige Consumer Healthcare 的目標價從 100.00 美元下調至 88.00 美元，並給予 “買入” 評級。Oppenheimer 在 10 月 21 日（星期二）的研究報告中將 Prestige Consumer Healthcare 的目標價從 82.00 美元下調至 72.00 美元，並給予 “跑贏大盤” 評級。Weiss Ratings 在 10 月 8 日（星期三）的研究報告中重新發布了對 Prestige Consumer Healthcare 的 “持有（c）” 評級。最後，Sidoti 在 9 月 24 日（星期三）的研究報告中將 Prestige Consumer Healthcare 的評級從 “中性” 上調至 “買入”，並設定了 80.00 美元的目標價。四位分析師對該股票給予 “買入” 評級，四位分析師給予 “持有” 評級。根據 MarketBeat 的數據，該公司的共識評級為 “適度買入”，平均目標價為 85.33 美元。</p>
<p><strong>獲取我們關於 PBH 的最新報告</strong></p>
<h2>Prestige Consumer Healthcare 股票上漲 0.2%</h2>
<p>NYSE:PBH 的股票在星期四以 62.42 美元開盤。該公司的 50 日移動平均線為 60.76 美元，200 日移動平均線為 67.61 美元。Prestige Consumer Healthcare 的 12 個月低點為 57.25 美元，12 個月高點為 90.04 美元。該股票的市值為 30 億美元，市盈率為 15.49，PEG 比率為 1.96，貝塔值為 0.39。該公司的速動比率為 2.51，流動比率為 3.70，債務與股本比率為 0.55。</p>
<h2>Prestige Consumer Healthcare 的機構交易</h2>
<p>幾家對沖基金最近對該公司的持倉進行了調整。Price T Rowe Associates Inc. MD 在第一季度將其在 Prestige Consumer Healthcare 的股份增加了 2.4%。Price T Rowe Associates Inc. MD 目前擁有 466,204 股該公司的股票，價值 40,081,000 美元，在此期間又增持了 11,112 股。Jane Street Group LLC 在第一季度將其在 Prestige Consumer Healthcare 的持倉增加了 204.0%。Jane Street Group LLC 目前擁有 104,802 股該公司的股票，價值 9,010,000 美元，在此期間又購買了 70,330 股。Rafferty Asset Management LLC 在第一季度將其在 Prestige Consumer Healthcare 的持倉增加了 16.0%。Rafferty Asset Management LLC 目前擁有 3,711 股該公司的股票，價值 319,000 美元，在此期間又購買了 513 股。OMERS ADMINISTRATION Corp 在第一季度購買了 Prestige Consumer Healthcare 的新股份，價值約 997,000 美元。最後，Magnetar Financial LLC 在第一季度購買了 Prestige Consumer Healthcare 的新股份，價值約 1,433,000 美元。目前 99.95% 的股票由機構投資者持有。</p>
<h2>Prestige Consumer Healthcare 的內部活動</h2>
<p>在相關消息中，副總裁 Jeffrey Zerillo 於 11 月 28 日（星期五）出售了 719 股該公司的股票。該股票以平均價格 60.00 美元出售，總價值為 43,140.00 美元。交易後，該副總裁在公司中持有 42,329 股，價值約 2,539,740 美元。這代表其持股比例減少了 1.67%。該交易已在向證券交易委員會提交的文件中披露，相關文件可通過此鏈接訪問。公司內部人士持有該公司 1.40% 的股票。</p>
<h2>關於 Prestige Consumer Healthcare</h2>
<p>（獲取免費報告）</p>
<p>Prestige Consumer Healthcare, Inc 是一家領先的品牌非處方（OTC）醫療產品製造商和營銷商。該公司專注於開發、收購和商業化多樣化的非處方藥物組合，旨在滿足消費者的常見健康需求，包括疼痛緩解、感冒和咳嗽、消化健康、眼部護理、皮膚護理和女性健康。</p>
<p>Prestige 的主要品牌包括 Clear Eyes（眼部健康）、Carmex（唇部護理）、Chloraseptic（喉嚨痛緩解）、Dramamine（暈動病）、Rolaids（抗酸藥）、Monistat（女性健康）、BC Powder（疼痛緩解）、Little Remedies（兒童感冒和氣體緩解）和 TheraTears（乾眼治療）。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Prestige Consumer Healthcare</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者警報：微型 “3 美元 AI 奇蹟股” 即將爆發</li>
<li>是否可以從資本利得税中扣除任何費用？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>忘記 AI，這將是下一個重大科技突破</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBCSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBCSA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Prestige Consumer Healthcare 嗎？</h2>
<p>在考慮 Prestige Consumer Healthcare 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Prestige Consumer Healthcare 並不在名單上。</p>
<p>雖然 Prestige Consumer Healthcare 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

普雷斯蒂奇

<p>Zacks Research 已將對 Prestige Consumer Healthcare 2027 年第一季度每股收益的預期上調至 1.24 美元，較之前的 1.23 美元有所增加。該公司的評級為 “持有”，全年每股收益的共識預期為 4.50 美元。分析師的評級意見不一，整體共識為 “適度買入”，平均目標價為 85.33 美元。該股票目前的交易價格為 62.42 美元，市值為 30 億美元</p>

<p>Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) - Zacks Research raised their Q1 2027 EPS estimates for Prestige Consumer Healthcare in a report released on Tuesday, December 23rd. Zacks Research analyst Team now forecasts that the company will post earnings of $1.24 per share for the quarter, up from their previous forecast of $1.23. Zacks Research currently has a &#34;Hold&#34; rating on the stock. The consensus estimate for Prestige Consumer Healthcare's current full-year earnings is $4.50 per share.</p>
<div class="lb-trans"><p>Prestige Consumer Healthcare Inc.（紐約證券交易所代碼：PBH - 免費報告）- Zacks Research 在 12 月 23 日（星期二）發佈的報告中上調了 Prestige Consumer Healthcare 2027 年第一季度每股收益的預期。Zacks Research 分析師團隊現在預測該公司本季度每股收益為 1.24 美元，高於之前預測的 1.23 美元。Zacks Research 目前對該股票的評級為 “持有”。Prestige Consumer Healthcare 當前全年的每股收益共識預期為 4.50 美元。</p>
</div><p>Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported $1.07 earnings per share for the quarter, beating the consensus estimate of $0.97 by $0.10. The business had revenue of $274.11 million for the quarter, compared to analysts' expectations of $257.14 million. Prestige Consumer Healthcare had a net margin of 18.09% and a return on equity of 12.43%. The firm's revenue for the quarter was down 3.4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.09 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS.</p>
<div class="lb-trans"><p>Prestige Consumer Healthcare（紐約證券交易所代碼：PBH - 獲取免費報告）最近於 11 月 6 日（星期四）公佈了季度財報。該公司報告本季度每股收益為 1.07 美元，超出市場共識預期的 0.97 美元，超出幅度為 0.10 美元。該業務本季度的收入為 2.7411 億美元，而分析師預期為 2.5714 億美元。Prestige Consumer Healthcare 的淨利潤率為 18.09%，股本回報率為 12.43%。與去年同期相比，該公司的季度收入下降了 3.4%。去年同期，該公司每股收益為 1.09 美元。Prestige Consumer Healthcare 已將 2026 財年的指導目標設定為每股收益 4.540-4.580 美元。</p>
</div><p>Several other equities analysts have also recently weighed in on PBH. Jefferies Financial Group dropped their price objective on Prestige Consumer Healthcare from $75.00 to $71.00 and set a &#34;hold&#34; rating on the stock in a research note on Monday, October 27th. Canaccord Genuity Group dropped their price target on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday, November 7th. Oppenheimer reduced their price objective on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an &#34;outperform&#34; rating for the company in a research report on Tuesday, October 21st. Weiss Ratings reissued a &#34;hold (c)&#34; rating on shares of Prestige Consumer Healthcare in a research report on Wednesday, October 8th. Finally, Sidoti upgraded Prestige Consumer Healthcare from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $80.00 target price on the stock in a research note on Wednesday, September 24th. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $85.33.</p>
<div class="lb-trans"><p>其他幾位股票分析師最近也對 PBH 發表了看法。Jefferies Financial Group 在 10 月 27 日（星期一）的研究報告中將 Prestige Consumer Healthcare 的目標價從 75.00 美元下調至 71.00 美元，並對該股票給予 “持有” 評級。Canaccord Genuity Group 在 11 月 7 日（星期五）的研究報告中將 Prestige Consumer Healthcare 的目標價從 100.00 美元下調至 88.00 美元，並給予 “買入” 評級。Oppenheimer 在 10 月 21 日（星期二）的研究報告中將 Prestige Consumer Healthcare 的目標價從 82.00 美元下調至 72.00 美元，並給予 “跑贏大盤” 評級。Weiss Ratings 在 10 月 8 日（星期三）的研究報告中重新發布了對 Prestige Consumer Healthcare 的 “持有（c）” 評級。最後，Sidoti 在 9 月 24 日（星期三）的研究報告中將 Prestige Consumer Healthcare 的評級從 “中性” 上調至 “買入”，並設定了 80.00 美元的目標價。四位分析師對該股票給予 “買入” 評級，四位分析師給予 “持有” 評級。根據 MarketBeat 的數據，該公司的共識評級為 “適度買入”，平均目標價為 85.33 美元。</p>
</div><p><strong>Get Our Latest Report on PBH</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 PBH 的最新報告</strong></p>
</div><h2>Prestige Consumer Healthcare Stock Up 0.2%</h2>
<div class="lb-trans"><h2>Prestige Consumer Healthcare 股票上漲 0.2%</h2>
</div><p>Shares of NYSE:PBH opened at $62.42 on Thursday. The business's 50 day moving average is $60.76 and its 200 day moving average is $67.61. Prestige Consumer Healthcare has a 12-month low of $57.25 and a 12-month high of $90.04. The stock has a market cap of $3.00 billion, a price-to-earnings ratio of 15.49, a PEG ratio of 1.96 and a beta of 0.39. The company has a quick ratio of 2.51, a current ratio of 3.70 and a debt-to-equity ratio of 0.55.</p>
<div class="lb-trans"><p>NYSE:PBH 的股票在星期四以 62.42 美元開盤。該公司的 50 日移動平均線為 60.76 美元，200 日移動平均線為 67.61 美元。Prestige Consumer Healthcare 的 12 個月低點為 57.25 美元，12 個月高點為 90.04 美元。該股票的市值為 30 億美元，市盈率為 15.49，PEG 比率為 1.96，貝塔值為 0.39。該公司的速動比率為 2.51，流動比率為 3.70，債務與股本比率為 0.55。</p>
</div><h2>Institutional Trading of Prestige Consumer Healthcare</h2>
<div class="lb-trans"><h2>Prestige Consumer Healthcare 的機構交易</h2>
</div><p>Several hedge funds have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD grew its stake in shares of Prestige Consumer Healthcare by 2.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 466,204 shares of the company's stock worth $40,081,000 after acquiring an additional 11,112 shares during the period. Jane Street Group LLC boosted its position in Prestige Consumer Healthcare by 204.0% during the first quarter. Jane Street Group LLC now owns 104,802 shares of the company's stock worth $9,010,000 after purchasing an additional 70,330 shares during the period. Rafferty Asset Management LLC boosted its position in Prestige Consumer Healthcare by 16.0% during the first quarter. Rafferty Asset Management LLC now owns 3,711 shares of the company's stock worth $319,000 after purchasing an additional 513 shares during the period. OMERS ADMINISTRATION Corp purchased a new position in shares of Prestige Consumer Healthcare in the first quarter worth about $997,000. Finally, Magnetar Financial LLC bought a new stake in shares of Prestige Consumer Healthcare in the first quarter valued at approximately $1,433,000. 99.95% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>幾家對沖基金最近對該公司的持倉進行了調整。Price T Rowe Associates Inc. MD 在第一季度將其在 Prestige Consumer Healthcare 的股份增加了 2.4%。Price T Rowe Associates Inc. MD 目前擁有 466,204 股該公司的股票，價值 40,081,000 美元，在此期間又增持了 11,112 股。Jane Street Group LLC 在第一季度將其在 Prestige Consumer Healthcare 的持倉增加了 204.0%。Jane Street Group LLC 目前擁有 104,802 股該公司的股票，價值 9,010,000 美元，在此期間又購買了 70,330 股。Rafferty Asset Management LLC 在第一季度將其在 Prestige Consumer Healthcare 的持倉增加了 16.0%。Rafferty Asset Management LLC 目前擁有 3,711 股該公司的股票，價值 319,000 美元，在此期間又購買了 513 股。OMERS ADMINISTRATION Corp 在第一季度購買了 Prestige Consumer Healthcare 的新股份，價值約 997,000 美元。最後，Magnetar Financial LLC 在第一季度購買了 Prestige Consumer Healthcare 的新股份，價值約 1,433,000 美元。目前 99.95% 的股票由機構投資者持有。</p>
</div><h2>Insider Activity at Prestige Consumer Healthcare</h2>
<div class="lb-trans"><h2>Prestige Consumer Healthcare 的內部活動</h2>
</div><p>In related news, VP Jeffrey Zerillo sold 719 shares of the company's stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $60.00, for a total value of $43,140.00. Following the transaction, the vice president owned 42,329 shares in the company, valued at approximately $2,539,740. This represents a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Company insiders own 1.40% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，副總裁 Jeffrey Zerillo 於 11 月 28 日（星期五）出售了 719 股該公司的股票。該股票以平均價格 60.00 美元出售，總價值為 43,140.00 美元。交易後，該副總裁在公司中持有 42,329 股，價值約 2,539,740 美元。這代表其持股比例減少了 1.67%。該交易已在向證券交易委員會提交的文件中披露，相關文件可通過此鏈接訪問。公司內部人士持有該公司 1.40% 的股票。</p>
</div><h2>About Prestige Consumer Healthcare</h2>
<div class="lb-trans"><h2>關於 Prestige Consumer Healthcare</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.</p>
<div class="lb-trans"><p>Prestige Consumer Healthcare, Inc 是一家領先的品牌非處方（OTC）醫療產品製造商和營銷商。該公司專注於開發、收購和商業化多樣化的非處方藥物組合，旨在滿足消費者的常見健康需求，包括疼痛緩解、感冒和咳嗽、消化健康、眼部護理、皮膚護理和女性健康。</p>
</div><p>Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).</p>
<div class="lb-trans"><p>Prestige 的主要品牌包括 Clear Eyes（眼部健康）、Carmex（唇部護理）、Chloraseptic（喉嚨痛緩解）、Dramamine（暈動病）、Rolaids（抗酸藥）、Monistat（女性健康）、BC Powder（疼痛緩解）、Little Remedies（兒童感冒和氣體緩解）和 TheraTears（乾眼治療）。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Prestige Consumer Healthcare</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Forget AI, This Will Be the Next Big Tech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Prestige Consumer Healthcare</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者警報：微型 “3 美元 AI 奇蹟股” 即將爆發</li>
<li>是否可以從資本利得税中扣除任何費用？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>忘記 AI，這將是下一個重大科技突破</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBCSA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=PBH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Prestige Consumer Healthcare Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Prestige Consumer Healthcare 嗎？</h2>
</div><p>Before you consider Prestige Consumer Healthcare, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Prestige Consumer Healthcare 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Prestige Consumer Healthcare 並不在名單上。</p>
</div><p>While Prestige Consumer Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Prestige Consumer Healthcare 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Zacks 研究對 PBH 第一季度的收益預測持樂觀態度